XRTX — XORTX Therapeutics Cashflow Statement
0.000.00%
- CA$7.26m
- CA$2.01m
Annual cashflow statement for XORTX Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | fx Final | fx Final | fx Final | Final | Final |
Net Income/Starting Line | -0.475 | -0.958 | -1.32 | -7.72 | -2.16 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 0.047 | 0.129 | -2.43 | -2.78 | -3.53 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 0.225 | 0.27 | -1.1 | 1.47 | -1.03 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Payable / Accrued Expenses | |||||
Cash from Operating Activities | -0.188 | -0.543 | -4.84 | -8.96 | -6.58 |
Capital Expenditures | -0.005 | -0.011 | -0.032 | -0.046 | -0.046 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 0 | — | — | — | — |
Acquisition of Business | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -0.005 | -0.011 | -0.032 | -0.046 | -0.046 |
Financing Cash Flow Items | -0.011 | -0.033 | -0.683 | -0.27 | -0.295 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 0.042 | 0.638 | 19.5 | 4.71 | -0.361 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -0.152 | 0.084 | 14.9 | -4.44 | -6.99 |